These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 7696185

  • 1. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
    Langton-Webster BC, Xuan JA, Brink JR, Salomon DS.
    Cell Growth Differ; 1994 Dec; 5(12):1367-72. PubMed ID: 7696185
    [Abstract] [Full Text] [Related]

  • 2. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
    Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK.
    Cancer Res; 1991 Sep 01; 51(17):4575-80. PubMed ID: 1678683
    [Abstract] [Full Text] [Related]

  • 3. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 4. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
    Nishikawa K, Rosenblum MG, Newman RA, Pandita TK, Hittelman WN, Donato NJ.
    Cancer Res; 1992 Sep 01; 52(17):4758-65. PubMed ID: 1380890
    [Abstract] [Full Text] [Related]

  • 5. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D, Williams JI, Pietras RJ.
    Oncogene; 2002 Apr 25; 21(18):2805-14. PubMed ID: 11973639
    [Abstract] [Full Text] [Related]

  • 6. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
    Rose WC, Basler GA.
    In Vivo; 1990 Apr 25; 4(6):391-6. PubMed ID: 2103379
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 11. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
    Song K, Cowan KH, Sinha BK.
    Oncol Res; 1999 Feb 15; 11(3):153-9. PubMed ID: 10527075
    [Abstract] [Full Text] [Related]

  • 12. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC.
    Clin Cancer Res; 2000 Aug 15; 6(8):3334-41. PubMed ID: 10955821
    [Abstract] [Full Text] [Related]

  • 13. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 14. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
    Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP.
    Cancer Res; 2005 Aug 01; 65(15):6789-800. PubMed ID: 16061661
    [Abstract] [Full Text] [Related]

  • 15. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
    Uslu R, Jewett A, Bonavida B.
    Gynecol Oncol; 1996 Aug 01; 62(2):282-91. PubMed ID: 8751562
    [Abstract] [Full Text] [Related]

  • 16. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
    Nilsson EE, Westfall SD, McDonald C, Lison T, Sadler-Riggleman I, Skinner MK.
    Cancer Chemother Pharmacol; 2002 Feb 15; 49(2):93-100. PubMed ID: 11862422
    [Abstract] [Full Text] [Related]

  • 19. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line.
    Koropatnick J, Kloth DM, Kadhim S, Chin JL, Cherian MG.
    J Pharmacol Exp Ther; 1995 Dec 15; 275(3):1681-7. PubMed ID: 8531144
    [Abstract] [Full Text] [Related]

  • 20. Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin.
    Marverti G, Giuseppina Monti M, Pegg AE, McCloskey DE, Bettuzzi S, Ligabue A, Caporali A, D'Arca D, Moruzzi MS.
    Carcinogenesis; 2005 Oct 15; 26(10):1677-86. PubMed ID: 15905201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.